Erkurt, Mehmet AliBerber, IlhamiTekgunduz, EmreDogu, Mehmet HilmiKorkmaz, SerdalDemir, CengizAydogdu, Ismet2025-05-102025-05-1020161473-050210.1016/j.transci.2016.01.0182-s2.0-84956890309https://doi.org/10.1016/j.transci.2016.01.018https://hdl.handle.net/20.500.14720/14930Kuku, Irfan/0000-0001-6126-0816; Dogu, Mehmet Hilmi/0000-0001-7237-2637; Demir, Cengiz/0000-0001-9856-184X; Altuntas, Fevzi/0000-0001-6872-3780; Berber, Ilhami/0000-0003-3312-8476; Erkurt, Mehmet Ali/0000-0002-3285-417X; Kaya, Emin/0000-0001-8605-8497We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. (c) 2016 Elsevier Ltd. All rights reserved.eninfo:eu-repo/semantics/closedAccessAutologous Stem Cell TransplantationCns LymphomaPcnslMethotrexateHigh-Dose ChemotherapyArticle541Q4Q3808426810141WOS:000374614700015